Family Offices Frontier Science Investing Expands Into Space and Longevity Biotech

Family offices frontier science investing is accelerating as wealthy Asian families expand allocations to sectors such as space technology and longevity biotech.

The Venture Network founder Lachezar Zanev said younger heirs are increasingly pursuing both outsized returns and social impact through emerging scientific industries.

Lower launch costs and improving satellite capabilities, alongside biotech advances moving toward clinical applications, are widening the opportunity set for patient private capital.

Singapore’s ecosystem is also improving access to family offices frontier science investing, with DBS-backed multi-family structures reaching about SGD1bn (USD780m) in assets and targeting SGD2bn by end-2026.

Deal flow is expanding as India’s Digantara raised USD50m and China’s LandSpace is targeting a roughly USD1bn Shanghai IPO, while AI-driven longevity player Gero has partnered with Pfizer.

The developments highlight how family offices frontier science investing is emerging as a new alternatives strategy for long-term capital.